New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects
M Huang, Y Lin, C Wang, L Deng, M Chen… - Drug resistance …, 2022 - Elsevier
Angiogenesis is a hallmark of cancer and is required for tumor growth and progression.
Antiangiogenic therapy has been revolutionarily developing and was approved for the …
Antiangiogenic therapy has been revolutionarily developing and was approved for the …
Sex differences in cancer mechanisms
JB Rubin, JS Lagas, L Broestl, J Sponagel… - Biology of sex …, 2020 - Springer
We now know that cancer is many different diseases, with great variation even within a
single histological subtype. With the current emphasis on developing personalized …
single histological subtype. With the current emphasis on developing personalized …
The anti-VEGF (R) drug discovery legacy: improving attrition rates by breaking the vicious cycle of angiogenesis in cancer
Simple Summary Several anti-angiogenic drugs have been approved for cancer treatment,
alone or in combination with other anti-tumoral agents. Angiogenesis inhibitors cause drug …
alone or in combination with other anti-tumoral agents. Angiogenesis inhibitors cause drug …
Antiangiogenic therapy in colorectal cancer
K Mody, C Baldeo, T Bekaii-Saab - The Cancer Journal, 2018 - journals.lww.com
Colorectal carcinoma is the third most common cancer worldwide. Approximately 20% of
patients with colorectal cancer will have metastatic disease at the time of initial diagnosis …
patients with colorectal cancer will have metastatic disease at the time of initial diagnosis …
FoxM1: Repurposing an oncogene as a biomarker
The past few decades have witnessed a tremendous progress in understanding the biology
of cancer, which has led to more comprehensive approaches for global gene expression …
of cancer, which has led to more comprehensive approaches for global gene expression …
Vascular endothelial growth factor-D (VEGF-D): An angiogenesis bypass in malignant tumors
SMZ Bokhari, P Hamar - International Journal of Molecular Sciences, 2023 - mdpi.com
Vascular endothelial growth factors (VEGFs) are the key regulators of vasculogenesis in
normal and oncological development. VEGF-A is the most studied angiogenic factor …
normal and oncological development. VEGF-A is the most studied angiogenic factor …
[HTML][HTML] Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind …
J Tabernero, RR Hozak, T Yoshino, AL Cohn… - Annals of …, 2018 - Elsevier
Abstract Background The phase III RAISE trial (NCT01183780) demonstrated that the
vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody …
vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody …
The evolving biomarker landscape for treatment selection in metastatic colorectal cancer
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …
important improvements in patient outcomes. However, it is still necessary to increase …
Therapeutic targeting of the colorectal tumor stroma
Colorectal tumors have been classified based on histologic factors, genetic factors, and
consensus molecular subtypes, all of which affect the tumor microenvironment. Elements of …
consensus molecular subtypes, all of which affect the tumor microenvironment. Elements of …
Emerging roles for VEGF-D in human disease
SA Stacker, MG Achen - Biomolecules, 2018 - mdpi.com
Blood vessels and lymphatic vessels are located in many tissues and organs throughout the
body, and play important roles in a wide variety of prevalent diseases in humans. Vascular …
body, and play important roles in a wide variety of prevalent diseases in humans. Vascular …